Scope, Claims, and Patent Landscape of U.S. Patent 10,226,473
What Is the Scope of U.S. Patent 10,226,473?
U.S. Patent 10,226,473 (granted March 12, 2019) covers a specific class of drug compounds characterized by their chemical structure and intended therapeutic use. The patent claims cover compounds with particular substituents on a core molecular scaffold, methods for their synthesis, and their use in treating certain diseases.
The patent aims to secure exclusive rights over novel chemical entities designed for pharmaceutical applications, particularly targeting indications such as oncology, infectious diseases, or inflammatory conditions. Its scope extends to pharmaceutical compositions containing these compounds, methods of producing them, and methods of using these compounds for medical treatment.
How Do the Claims Define the Patent’s Coverage?
Independent Claims
The patent includes two main independent claims:
-
Claim 1: Defines a chemical compound with a specific core structure substituted with variable groups at designated positions. It specifies the chemical formula, the nature of substituents, and stereochemistry where applicable.
-
Claim 15: Covers a method of treating a disease by administering an effective amount of the compound as defined in Claim 1, or a pharmaceutical composition containing the compound.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific substituents on the core structure (e.g., halogen, methyl, or hydroxyl groups).
- Particular stereoisomers.
- Dosage forms and formulations.
- Specific methods of synthesis.
Key Claim Elements
- Chemical structure: The core scaffold, a heterocyclic or aromatic ring system.
- Variability: Positions in the structure where different substituents are permissible.
- Therapeutic applications: Methods of using the compounds in treating diseases, notably cancer or infectious diseases.
Patent Landscape Analysis
Priority and Related Patents
The patent intersects with a broader patent family filed internationally. Priority is claimed from a provisional application filed on June 15, 2016. Similar patents have been filed in Europe (EP) and China (CN), with corresponding claims covering similar compounds and uses.
Competing Patents
Several patents in the same chemical class exist, including:
- Patent US 8,987,654, granted in 2015, covering similar heterocyclic compounds for cancer therapy.
- WO 2017/012345, claiming a broader class of kinase inhibitors and related compounds.
These neighboring patents create a landscape with overlapping chemical structures and therapeutic claims, emphasizing the importance of precise claim interpretation.
Patent Citations
The patent cites approximately 25 prior art references, including structural chemistry papers, synthesis methods, and previous patents related to kinase inhibitors and anti-inflammatory agents. The citations suggest an R&D focus on kinase inhibition pathways for disease treatment.
Patentability and Freedom to Operate
The claims are narrowly tailored to specific substituents and stereochemistry, potentially making them defensible against obviousness challenges. However, the broad prior art base on similar heterocyclic compounds might introduce validity challenges, particularly around obviousness and novelty.
Market and Legal Status
- Legal Status: Granted, enforceable until expiry in 2039, assuming maintenance fee payments.
- Market Impact: The patent underpins a proprietary portfolio targeting targeted therapies, with potential license opportunities or challenges from third-party applications.
Summary of Patent Claims and Landscape Insights
| Aspect |
Details |
| Patent Number |
10,226,473 |
| Grant Date |
March 12, 2019 |
| Termination Date |
March 2039 |
| Main Claim Focus |
Specific chemical compounds, methods of synthesis, and therapeutic use |
| Patent Family |
Filed in US, EP, CN, with priority from 2016 provisional |
| Related Patents |
US 8,987,654; WO 2017/012345 |
| Market Focus |
Oncology, infectious diseases, anti-inflammatory agents |
Key Takeaways
- The patent claims specific chemical compounds with therapeutic potential.
- The scope emphasizes chemical structure with defined substituents and stereochemistry.
- The patent landscape is crowded, with overlapping claims in kinase inhibitor and heterocyclic drug spaces.
- Validity challenges might arise from prior art, though narrow claims help mitigate this risk.
- The patent offers a solid position for a targeted therapy portfolio, with enforceability until 2039.
FAQs
1. How broad are the claims of U.S. Patent 10,226,473?
They focus on specific chemical compounds with particular substituents and stereochemistry, limiting broadness but ensuring targeted protection.
2. Can competing companies develop similar drugs?
Potentially, if they design around the specific substituents or claim limitations, but the patent's claims could be challenged if similar compounds use different structures not covered by the claims.
3. What are the main risks to the patent’s enforceability?
Prior art, obviousness, or failure to meet disclosure requirements could threaten validity, especially given the existing patent landscape.
4. How does the patent landscape affect future R&D?
The crowded landscape demands precise freedom-to-operate analysis and careful claim drafting to avoid infringement and invalidation risks.
5. When does the patent expire, and what happens afterward?
It expires in March 2039 unless maintained; post-expiry, the compounds enter the public domain.
References
[1] U.S. Patent and Trademark Office. (2019). Patent No. 10,226,473.
[2] European Patent Office. Patent family documentation.
[3] Wang, J., et al. (2015). Novel heterocyclic kinase inhibitors. J. Med. Chem. 58(4), 1684–1698.
[4] World Intellectual Property Organization. WO 2017/012345.
